Abbott (ABT) Reports Positive 12-Month VOLT-AF IDE Study Results

Abbott Laboratories (ABT) released positive 12-month outcomes from its VOLT-AF IDE study evaluating the novel dual-chamber pacemaker. The results, published on February 7, 2026, indicate a significant reduction in heart failure hospitalizations and improved quality of life for patients with heart failure and reduced ejection fraction. Key findings include a 32% lower risk of hospitalization for heart failure and a 28% reduction in heart-related readmissions. The study enrolled 1,200 patients across 50 centers and followed them for 12 months. The findings support the device's potential to become a standard treatment option in Abbott's evolving cardiovascular portfolio.